Anne Llewellyn examines the consequences and underwriting ramifications of this little known disease.
Sarcoidosis is a progressive, inflammatory disease of unknown cause characterised by the formation of granulomas, abnormal nodules of inflamed tissue that can affect any organ, altering its structure and function. It primarily affects young and middle aged adults. Around 20% of those diagnosed with sarcoidosis will experience functional impairment, and the mortality rate is about 5%. A disclosure of sarcoidosis is therefore significant at underwriting stage, but as 80% of sufferers have no impairment the majority of applicants with this condition will be accepted at standard rates or wit...
To continue reading this article...
Join Professional Adviser for free
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes